Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...
Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US ...
Apple stock rises after falling Thursday by the most since August, Alphabet stock is up after the Supreme Court upholds a ban ...
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...
Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback